LINK:  https://bswhealth.webex.com/bswhealth/j.php?MTID=m3b29d8677be42c12114ce2c45b2b2eab

OBJECTIVES: Upon completion of this activity, the participant should be able to:  (1) Review the background of human immunodeficiency virus (HIV) and end-stage renal disease (ESRD) in HIV- positive recipients, (2) Discuss the manager of HIV with highly active antiretroviral therapy (HAART) and associated drug-drug interactions with immunosuppressive agents, (3) Explain the introduction, maintenance immunosuppression strategies, and opportunistic infection prophylaxis in HIV- positive kidney transplant (KT) recipients, (4) Describe patient and graft outcomes of KT in HIV- positive recipients.

FACULTY DISCLOSURE: Jenny Lee, PharmD, has no relevant financial relationship(s) with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

PLANNER DISCLOSURE: James Trotter, MD, Sumeet Asrani, MD, Gregory McKenna, MD, and Kathy Brown, RN, CCTC, have no relevant financial relationship(s) to disclose with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CEPTC Credit: The American Board for Transplant Certification (ABTC) has been applied for educational offering for up to 1 Category 1 Continuing Education Point for Transplant Certification (CEPTCs).

For information, please contact Karina Pena at [email protected]